Product lifecycle management company Dassault Systèmes has announced it will acquire clinical cloud...
Dassault to enhance clinical tech with $5.8bn Medidata acquisition
Product lifecycle management company Dassault Systèmes has announced it will acquire clinical cloud solution provider Medidata Solutions in an all-cash transaction.
Characterising Eastern China’s pharmaceutical manufacturing market: Shandong and Jiangsu
Due to the high number of pharmaceutical facilities in Eastern China, this article focuses on Eastern provinces: those north of the Yangtze River.
Elemental Impurity Analysis in Pharmaceuticals and Implementation of ICH Q3D
Elemental impurities have been a hot topic since 2009 when the International Conference of Harmonisation (ICH) commenced work on a new standard to provide a global policy to limit these impurities in drug products and ingredients.
How Virtualisation Can Help Electronic Data Retention
One of the most discussed topics currently affecting good manufacturing practices (GMP) laboratories, data integrity involves conforming to fundamental elements of quality: attributable, legible, cotemporaneous, original, and accurate (ALCOA). Of these, legibility presents a particularly tough challenge.
Liposomes protect, transport and release your drug at the right place and time. By this, a reduced dose achieves better efficacy and avoids side effects with a non-invasive application. A liposomal formulation can clearly improve the therapeutic index of your drug.
As small molecules continue to dominate industry approvals, API manufacturing rises in importance
64% of New Molecule Entity approvals by European and US authorities in 2018 were for small molecule drugs, according to GlobalData.
ILC Dover Manufacturing Facility
In May 2019, ILC Dover opened a manufacturing facility in Ireland to produce the company’s pharmaceutical and biopharmaceutical product lines. The plant is designed to strengthen the company's single-use powder handling solutions business.
Orphan approval outsourcing hits 5-year high, reveals future opportunity for CMOs
Special designations are good for CMOs: orphan and other accelerated drugs are more likely to be contract manufactured than products that go through standard review.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.